Abstract:Background & Aims: Abnormal activation of mTOR through loss of tuberous sclerosis complex (Tsc) frequently occurs in hepatocellular carcinoma (HCC). Mutant Kras could induce aggressive HCCs. Here, we aim to identify the predictive or prognostic biomarkers for HCC patients with Kras mutant and mTOR hyperactivation, and to provide potential therapeutic approaches for this subtype of HCCs. Methods: We generated transgenic mice in which hepatocytic mTOR was hyperactivated through Tsc1 insufficiency with or without oncogenic KrasG12D. Bioinformatics and gain- or loss-of-function studies were used to illustrate the mechanisms underlying oncogenic pathway alterations. Transcriptional profiling was used to identify biomarker for the subtype of HCC. The therapeutic efficacy of targeting mTOR was tested in a liver orthotropic homogeneous murine model. Results: Oncogenic KrasG12D facilitated mTOR activation via the Mek/Erk/ROS axis, leading to HCC tumorigenesis and metastasis. Inhibition of Mek/Erk enhanced the anticancer effect of mTOR inhibitor via reduction of mTOR activity. Paternally expressed 3 (PEG3) was responsible for Kras/Erk- and mTOR-driven HCC. Elevated PEG3 protein interacted with STAT3 and promoted its transcriptional activity, resulting in the upregulation of proliferation- and metastasis-related proteins. Targeting mTOR significantly inhibited these actions in vitro and in vivo. Moreover, in clinical samples, PEG3 was identified as a new poor prognostic marker for HCC patients with Kras/Erk and mTOR hyperactivation. Conclusion: These findings reveal the underlying mechanism of hepatocytic Kras/Erk-driven mTOR activation and its downstream targets (PEG3 and STAT3) in HCC, identify PEG3 as a new prognostic biomarker for HCC with Kras/Erk and mTOR hyperactivation, and provide a potential therapeutic strategy for this subset of HCC patients.

Brain-expressed X-linked 2 is Pivotal for Hyperactive Mechanistic Target of Rapamycin (Mtor)-Mediated Tumorigenesis.

Silencing Of Brain-Expressed X-Linked 2 (Bex2) Promotes Colorectal Cancer Metastasis Through The Hedgehog Signaling Pathway

TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex

Bex2 Promotes Tumor Proliferation In Colorectal Cancer

A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome

Mtor-Dependent Upregulation of Xct Blocks Melanin Synthesis and Promotes Tumorigenesis

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

The Mtor–s6k Pathway Links Growth Signalling to DNA Damage Response by Targeting RNF168

A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway

Tuberous sclerosis-2 tumor suppressor modulates ERK and B-Raf activity in transformed renal epithelial cells

AKT-mediated phosphorylation of TSC2 controls stimulus and tissue-specific mTORC1 signaling and organ growth

Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling

Aberrant Mtor/Autophagy/Nurr1 Signaling Is Critical For Tsc-Associated Tumor Development

Mtor Promotes Tissue Factor Expression and Activity in EGFR-Mutant Cancer

mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK

UBE2S exerts oncogenic activities in urinary bladder cancer by ubiquitinating TSC1

OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ

Tsc Tumour Suppressor Proteins Antagonize Amino-Acid–tor Signalling

TSC2-mTORC1 axis regulates morphogenesis and neurological function of Gli1+ adult-born dentate granule cells

FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression

mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis